Rationale: There are no direct comparisons of sotatercept to add-on therapies approved for
PAH. Objective: This study aimed to compare the efficacy and safety of add-on sotatercept …

Pulmonary arterial hypertension (PAH) is a rare pulmonary vascular disorder, wherein mean
systemic arterial pressure (mPAP) becomes abnormally high because of aberrant changes …

Abstract Background and Aims Effective therapies that target three main signalling pathways
are approved to treat pulmonary arterial hypertension (PAH). However, there are few large …

Background Pulmonary arterial hypertension (PAH) is characterized by lipid accumulation
and mitochondrial dysfunction. This study was designed to investigate the effects of hypoxia …

The treatment landscape for PAH has evolved dramatically over the past 30 years. 3
Medications targeting the endothelin, nitric oxide, and prostacyclin pathways have been …

Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by
elevated pulmonary artery pressure and vascular remodeling, resulting in poor prognosis …

During the COVID-19 pandemic, several drugs were repositioned and combined to quickly
find a way to mitigate the effects of the infection. However, the adverse effects of these …

Introduction Respiratory diseases encompass a diverse range of conditions that significantly
impact global morbidity and mortality. While common diseases like asthma and COPD …

Objectives To describe how systematic reviews with network meta-analyses (NMAs) that
used the Grading of Recommendations Assessment, Development, and Evaluation …

Background The efficacy of iloprost in treating pulmonary arterial hypertension (PAH) is
controversial. Adverse reactions such as hypotension may occur during treatment …